A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

被引:0
作者
Heather A. Wakelee
Gary Middleton
David Dunlop
Rodryg Ramlau
Natasha Leighl
Desiree Hao
Arturo Lopez-Anaya
Petr Zatloukal
Charlotte D. Jacobs
机构
[1] Stanford University and Stanford Cancer Institute,Division of Oncology, Department of Medicine
[2] St. Luke’s Cancer Centre,Third Faculty of Medicine
[3] Royal Surrey County Hospital,undefined
[4] Beatson West of Scotland Cancer Centre,undefined
[5] Poznan University of Medical Sciences,undefined
[6] Princess Margaret Hospital,undefined
[7] Tom Baker Cancer Centre,undefined
[8] Eisai,undefined
[9] Inc.,undefined
[10] Charles University,undefined
[11] Faculty Hospital Bulovka and Postgraduate Medical Institute,undefined
[12] Forest Laboratories,undefined
[13] Inc.,undefined
来源
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词
Bexarotene; Pharmacokinetics; Cisplatin; Vinorelbine; Non-small-cell lung cancer;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:815 / 824
页数:9
相关论文
共 178 条
[1]  
Andersson A(1996)Pharmacokinetics of cisplatin and its monohydrated complex in humans J Pharm Sci 85 824-827
[2]  
Fagerberg J(2008)Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II J Clin Oncol 26 1879-1885
[3]  
Lewensohn R(1994)Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties J Med Chem 37 408-414
[4]  
Ehrsson H(2002)The role of retinoid X receptor messenger RNA expression in curatively resected non-small cell lung cancer Clin Cancer Res 8 438-443
[5]  
Blumenschein GR(2005)Comprehensive expression analysis of retinoic acid receptors and retinoid X receptors in non-small cell lung cancer: implications for tumor development and prognosis Carcinogenesis 26 525-530
[6]  
Khuri FR(1993)Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity Cancer Surv 17 189-217
[7]  
von Pawel J(1996)A decade of molecular biology of retinoic acid receptors Faseb J 10 940-954
[8]  
Gatzemeier U(2001)Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results J Clin Oncol 19 2456-2471
[9]  
Miller WH(2002)Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer Cancer Chemother Pharmacol 49 48-56
[10]  
Jotte RM(2005)The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells Lung Cancer 50 9-18